{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T19:03:37Z","timestamp":1790708617430,"version":"4.1.0"},"reference-count":41,"publisher":"Oxford University Press (OUP)","issue":"Supplement_E","license":[{"start":{"date-parts":[[2020,6,4]],"date-time":"2020-06-04T00:00:00Z","timestamp":1591228800000},"content-version":"vor","delay-in-days":67,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Stable ischaemic heart disease is a frequent and very heterogeneous condition. Drug therapy is important, in these patients, for improving their prognosis and controlling their symptoms. The typical clinical manifestation of obstructive coronary disease is angina pectoris. This symptom can be improved by various classes of compounds, namely beta-blockers (BBs), calcium antagonist, and nitrates. More recently, ranolazine and ivabradine have been introduced. All these drugs have been proven to reduce significantly angina. On the other hand, there are no evidences supporting improvement in prognosis, besides for the use of BBs, in patients with previous myocardial infarction (MI) or systolic dysfunction. Besides drugs for symptoms control, these patients also receive antiplatelet drugs, specifically aspirin, and lipid lowering compounds such as statins. Furthermore, recent evidences supported the use of low doses direct anticoagulant, or a second antiplatelet agent in patients with previous MI. Similarly, a very low LDL cholesterol level, such as obtained with PCKS9 inhibitors, seems very beneficial in these patients. It is possible that in the near future a specific role for neo-angiogenesis factors and cellular therapies, could be proven, albeit, presently these treatments are not supported by solid evidences.<\/jats:p>","DOI":"10.1093\/eurheartj\/suaa060","type":"journal-article","created":{"date-parts":[[2020,6,4]],"date-time":"2020-06-04T09:13:08Z","timestamp":1591261988000},"page":"E54-E59","source":"Crossref","is-referenced-by-count":21,"title":["Treatment of stable ischaemic heart disease: the old and the new"],"prefix":"10.1093","volume":"22","author":[{"given":"Andrea","family":"Santucci","sequence":"first","affiliation":[{"name":"S.C. di Cardiologia, Ospedale S. Maria della Misericordia, Perugia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Riccini","sequence":"first","affiliation":[{"name":"S.C. di Cardiologia, Ospedale S. Maria della Misericordia, Perugia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Cavallini","sequence":"first","affiliation":[{"name":"S.C. di Cardiologia, Ospedale S. Maria della Misericordia, Perugia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,3,29]]},"reference":[{"key":"2020060405103655600_suaa060-B1","doi-asserted-by":"crossref","first-page":"256","DOI":"10.21037\/atm.2016.06.33","article-title":"Epidemiology of coronary heart disease and acute coronary syndrome","volume":"4","author":"Sanchis-Gomar","year":"2016","journal-title":"Ann Transl Med"},{"key":"2020060405103655600_suaa060-B2","doi-asserted-by":"crossref","first-page":"63","DOI":"10.7861\/clinmedicine.13-1-63","article-title":"Pharmacological treatment of chronic stable angina pectoris","volume":"13","author":"Tarkin","year":"2013","journal-title":"Clin Med (Lond)"},{"key":"2020060405103655600_suaa060-B3","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.acvd.2011.08.001","article-title":"Update on the medical treatment of stable angina","volume":"104","author":"Gayet","year":"2011","journal-title":"Arch Cardiovasc Dis"},{"key":"2020060405103655600_suaa060-B4","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1177\/1074248417698224","article-title":"Antianginal therapy for stable ischemic heart disease: a contemporary review","volume":"22","author":"Padala","year":"2017","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"2020060405103655600_suaa060-B5","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1136\/bmj.318.7200.1730","article-title":"beta Blockade after myocardial infarction: systematic review and meta regression analysis","volume":"318","author":"Freemantle","year":"1999","journal-title":"BMJ"},{"key":"2020060405103655600_suaa060-B6","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1136\/heartjnl-2014-305719","article-title":"Prognostic impact of \u03b2-blocker use in patients with stable coronary artery disease","volume":"100","author":"Bauters","year":"2014","journal-title":"Heart"},{"key":"2020060405103655600_suaa060-B7","doi-asserted-by":"crossref","first-page":"e44","DOI":"10.1016\/j.jacc.2012.07.013","article-title":"2012 ACCF\/AHA\/ACP\/AATS\/PCNA\/SCAI\/STS Guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons","volume":"60","author":"Fihn","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"2020060405103655600_suaa060-B8","doi-asserted-by":"crossref","first-page":"2949","DOI":"10.1093\/eurheartj\/eht296","article-title":"2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology","volume":"34","author":"Task Force","year":"2013","journal-title":"Eur Heart J"},{"key":"2020060405103655600_suaa060-B9","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1161\/01.CIR.90.2.762","article-title":"Effects of treatment on outcome in mildly symptomatic patients with ischemia during daily life. The Atenolol Silent Ischemia Study (ASIST)","volume":"90","author":"Pepine","year":"1994","journal-title":"Circulation"},{"key":"2020060405103655600_suaa060-B10","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1093\/oxfordjournals.eurheartj.a014699","article-title":"The Total Ischaemic Burden European Trial (TIBET). Effects of atenolol, nifedipine SR and their combination on the exercise test and the total ischaemic burden in 608 patients with stable angina. The TIBET Study Group","volume":"17","author":"Fox","year":"1996","journal-title":"Eur Heart J"},{"key":"2020060405103655600_suaa060-B11","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1093\/oxfordjournals.eurheartj.a014695","article-title":"Effects of metoprolol vs verapamil in patients with stable angina pectoris. The Angina Prognosis Study in Stockholm (APSIS)","volume":"17","author":"Rehnqvist","year":"1996","journal-title":"Eur Heart J"},{"key":"2020060405103655600_suaa060-B12","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1177\/1741826711409325","article-title":"Long-term beta blockers for stable angina: systematic review and meta-analysis","volume":"19","author":"Shu de","year":"2012","journal-title":"Eur J Prev Cardiol"},{"key":"2020060405103655600_suaa060-B13","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1001\/jama.2012.12559","article-title":"-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease","volume":"308","author":"Bangalore","year":"2012","journal-title":"JAMA"},{"key":"2020060405103655600_suaa060-B14","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1161\/CIRCOUTCOMES.114.001073","article-title":"\u03b2-blockers and cardiovascular events in patients with and without myocardial infarction: post hoc analysis from the CHARISMA trial","volume":"7","author":"Bangalore","year":"2014","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"2020060405103655600_suaa060-B15","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1097\/CRD.0b013e3181c8e14a","article-title":"Nitrates and nitrites in the treatment of ischemic cardiac disease","volume":"18","author":"Nossaman","year":"2010","journal-title":"Cardiol Rev"},{"key":"2020060405103655600_suaa060-B16","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/0735-1097(95)00498-X","article-title":"Six-month effects of early treatment with lisinopril and transdermal glyceryl trinitrate singly and together withdrawn six weeks after acute myocardial infarction: the GISSI-3 trial. Gruppo Italiano per lo Studio della Sopravvivenza nell\u2019Infarto Miocardico","volume":"27","year":"1996","journal-title":"J Am Coll Cardiol"},{"key":"2020060405103655600_suaa060-B17","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/S0140-6736(95)90865-X","article-title":"ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group","volume":"345","year":"1995","journal-title":"Lancet"},{"key":"2020060405103655600_suaa060-B18","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.ijcard.2010.05.019","article-title":"Nitrates for stable angina: a systematic review and meta-analysis of randomized clinical trials","volume":"146","author":"Wei","year":"2011","journal-title":"Int J Cardiol"},{"key":"2020060405103655600_suaa060-B19","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/S0735-1097(87)80056-6","article-title":"Sustained release verapamil, a once daily preparation: objective evaluation using exercise testing, ambulatory monitoring and blood levels in patients with stable angina","volume":"9","author":"Kohli","year":"1987","journal-title":"J Am Coll Cardiol"},{"key":"2020060405103655600_suaa060-B20","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S0140-6736(04)16980-8","article-title":"Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomised controlled trial","volume":"364","author":"Poole-Wilson","year":"2004","journal-title":"Lancet"},{"key":"2020060405103655600_suaa060-B21","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.amjmed.2008.09.043","article-title":"Long-acting calcium antagonists in patients with coronary artery disease: a meta-analysis","volume":"122","author":"Bangalore","year":"2009","journal-title":"Am J Med"},{"key":"2020060405103655600_suaa060-B22","first-page":"CD003614","article-title":"Trimetazidine for stable angina","volume":"3","author":"Ciapponi","year":"2005","journal-title":"Cochrane Database Syst Rev"},{"key":"2020060405103655600_suaa060-B23","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1161\/CIRCULATIONAHA.105.597500","article-title":"Ranolazine for the treatment of chronic angina and potential use in other cardiovascular conditions","volume":"113","author":"Chaitman","year":"2006","journal-title":"Circulation"},{"key":"2020060405103655600_suaa060-B24","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1016\/j.jacc.2003.11.045","article-title":"Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina","volume":"43","author":"Chaitman","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"2020060405103655600_suaa060-B25","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1001\/jama.291.3.309","article-title":"Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial","volume":"291","author":"Chaitman","year":"2004","journal-title":"JAMA"},{"key":"2020060405103655600_suaa060-B26","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1093\/eurheartj\/ehi495","article-title":"Effects of ranolazine on exercise tolerance and HbA1c in patients with chronic angina and diabetes","volume":"27","author":"Timmis","year":"2006","journal-title":"Eur Heart J"},{"key":"2020060405103655600_suaa060-B27","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.jacc.2006.05.044","article-title":"Antianginal efficacy of ranolazine when added to treatment with amlodipine: the ERICA (Efficacy of Ranolazine in Chronic Angina) trial","volume":"48","author":"Stone","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"2020060405103655600_suaa060-B28","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1001\/jama.297.16.1775","article-title":"Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: the MERLIN-TIMI 36 randomized trial","volume":"297","author":"Morrow","year":"2007","journal-title":"JAMA"},{"key":"2020060405103655600_suaa060-B29","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1016\/j.jacc.2009.01.037","article-title":"Efficacy of ranolazine in patients with chronic angina observations from the randomized, double-blind, placebo-controlled MERLIN-TIMI (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Segment Elevation Acute Coronary Syndromes) 36 trial","volume":"53","author":"Wilson","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"2020060405103655600_suaa060-B30","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/S0140-6736(15)00459-6","article-title":"Ranolazine in patients with incomplete revascularisation after percutaneous coronary intervention (RIVER-PCI): a multicentre, randomised, double-blind, placebo-controlled trial","volume":"387","author":"Weisz","year":"2016","journal-title":"Lancet"},{"key":"2020060405103655600_suaa060-B31","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/S0140-6736(08)61170-8","article-title":"Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial","volume":"372","author":"Fox","year":"2008","journal-title":"Lancet"},{"key":"2020060405103655600_suaa060-B32","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa1406430","article-title":"Ivabradine in stable coronary artery disease without clinical heart failure","volume":"371","author":"Fox","year":"2014","journal-title":"N Engl J Med"},{"key":"2020060405103655600_suaa060-B33","doi-asserted-by":"crossref","first-page":"5.","DOI":"10.1007\/s11883-015-0553-2","article-title":"Dual antiplatelet therapy in patients with stable ischemic heart disease","volume":"18","author":"Keach","year":"2016","journal-title":"Curr Atheroscler Rep"},{"key":"2020060405103655600_suaa060-B34","doi-asserted-by":"crossref","first-page":"56.","DOI":"10.1007\/s11883-017-0698-2","article-title":"Antiplatelet therapy for secondary prevention of vascular disease complications","volume":"19","author":"Goli","year":"2017","journal-title":"Curr Atheroscler Rep"},{"key":"2020060405103655600_suaa060-B35","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1056\/NEJMoa1500857","article-title":"Long-term use of ticagrelor in patients with prior myocardial infarction","volume":"372","author":"Bonaca","year":"2015","journal-title":"N Engl J Med"},{"key":"2020060405103655600_suaa060-B36","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S0140-6736(17)32458-3","article-title":"Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial","volume":"391","author":"Connolly","year":"2018","journal-title":"Lancet"},{"key":"2020060405103655600_suaa060-B37","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N Engl J Med"},{"key":"2020060405103655600_suaa060-B38","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"key":"2020060405103655600_suaa060-B39","doi-asserted-by":"crossref","first-page":"i47","DOI":"10.1093\/rheumatology\/kex432","article-title":"Cardiac and renal protective effects of urate-lowering therapy","volume":"57(suppl_1)","author":"Richette","year":"2018","journal-title":"Rheumatology (Oxford"},{"key":"2020060405103655600_suaa060-B40","doi-asserted-by":"crossref","first-page":"e12461.","DOI":"10.1111\/1755-5922.12461","article-title":"Vascular endothelial growth factor gene transfer therapy for coronary artery disease: a systematic review and meta-analysis","volume":"36","author":"Yuan","year":"2018","journal-title":"Cardiovasc Ther"},{"key":"2020060405103655600_suaa060-B41","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1016\/j.jcin.2016.05.003","article-title":"The RENEW Trial: efficacy and safety of intramyocardial autologous CD34(+) cell administration in patients with refractory angina","volume":"9","author":"Povsic","year":"2016","journal-title":"JACC Cardiovasc Interv"}],"container-title":["European Heart Journal Supplements"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/eurheartjsupp\/article-pdf\/22\/Supplement_E\/E54\/33342583\/suaa060.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/eurheartjsupp\/article-pdf\/22\/Supplement_E\/E54\/33342583\/suaa060.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,4]],"date-time":"2020-06-04T09:13:19Z","timestamp":1591261999000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartjsupp\/article\/22\/Supplement_E\/E54\/5851034"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,29]]},"references-count":41,"journal-issue":{"issue":"Supplement_E","published-online":{"date-parts":[[2020,3,29]]},"published-print":{"date-parts":[[2020,6,1]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/suaa060","relation":{},"ISSN":["1520-765X","1554-2815"],"issn-type":[{"value":"1520-765X","type":"print"},{"value":"1554-2815","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,6]]},"published":{"date-parts":[[2020,3,29]]}}}